Patents by Inventor Dennis J. O'Callaghan

Dennis J. O'Callaghan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Equine Herpesvirus 1 Vaccine and Vector and Uses Thereof
    Publication number: 20130195918
    Abstract: We have constructed a mutant EHV-1 that is lacking the entire 12.7 kbp IR segment of the viral genome and found the mutant EHV-1 to be replication competent, to have the ability to replicate in mammalian cell types (including human cells), and to exhibit reduced virulence in the mouse model of EHV-1 virulence.
    Type: Application
    Filed: August 2, 2012
    Publication date: August 1, 2013
    Inventors: Dennis J. O'Callaghan, ByungChul Ahn, Yunfei Zhang, Nikolaus Osterrieder
  • Vaccine against equine herpesvirus type 1
    Patent number: 5795578
    Abstract: The present invention is directed to a gene encoding an envelope glycoprotein of equine herpesvirus type 1 (EHV-1), the glycoprotein D (gD) gene, its gene product and antibodies directed against gD polypeptides. The envelope glycoproteins of herpesvirus are major targets of the inmune response to herpesviral infection. Hence, an important aspect of this invention is directed towards a vaccine against EHV-1 and treatment of EHV-1 infection by anti-EHV-gD antibodies or antisera.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: August 18, 1998
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Dennis J. O'Callaghan
  • Immunogenic composition against equine herpesvirus type 1
    Patent number: 5707629
    Abstract: The present invention is directed to a gene encoding an envelope glycoprotein of equine herpesvirus type 1 (EHV-1), the glycoprotein D (gD) gene, its gene product and antibodies directed against gD polypeptides. The envelope glycoproteins of herpesvirus are major targets of the immune response to herpesviral infection. Hence, an important aspect of this invention is directed towards a vaccine against EHV-1 and treatment of EHV-1 infection by anti-EHV-gD antibodies or antisera.
    Type: Grant
    Filed: November 18, 1994
    Date of Patent: January 13, 1998
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Dennis J. O'Callaghan